Baillie Gifford & CO Cellectis S.A. Call Options Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding CLLS
# of Institutions
30Shares Held
10.8MCall Options Held
5.9KPut Options Held
1.4K-
Long Focus Capital Management, LLC San Juan, PR4.62MShares$8.4 Million0.36% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$3.36 Million0.0% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL1.44MShares$2.62 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.62 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$412,9120.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $82.8M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...